A Systematic Review Of Topotecan For Recurrent Ovarian Cancer

Objective: To assess the clinical effectiveness, safety and cost-effectiveness of topotecan for recurrent epithelial ovarian cancer compared to other anti-cancer agents.Method: The following electronic databases were searched: MEDLINE (1966～2005), EMBASE(1989～2004),CancerLit( 1996～2003), CBMdisc (1978～2005) by English language. CNKI (1994～2005) by Chinese language. The Cochrane Central Register of Controlled Trials (CENTRAL), The National Research Register, Health Technology Assessment database(HTA ), The Cochrane Library Issue 3, 2005. Correlative websites, such as 'google', were searched by hand. The studies included in the references of eligible studies were additionally searched. RCTs of chemotherapy before Dec 31, 2005 comparing topotecan with other agents for recurrent epithelial ovarian cancer were included. Eligible RCTs were assessed for quality by two reviewers independently: criteria of concealment of treatment, blinding, standard validity and reliability of outcome measures, withdraw rate, intention-to-treat analysis and homogeneity between centers were analyzed for each study. All data were performed by a Meta analysis.